Tradercommunity Clickoptions Forum

[Newsagent]

PR inside: Alligator Bioscience AB Reports Financial Results for Q2 2025 and Provides ...

(PR-inside.com) GMP manufacturing completed, paediatric waiver granted, positive outcome from FDA and EMA interactions; advancing mitazalimab toward Phase 3 readiness

Biomarker data from OPTIMIZE-1 presented at ASCO, supporting patient stratification and clinical potential

Warrant programme TO 12 completed, with gross proceeds of SEK 61 million and further strengthening financial position

LUND, SE / ACCESS Newswire / July 10, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX)

"With key regulatory and manufacturing milestones achieved for mitazalimab and strengthened financials, we remain focused on identifying a strategic partner and initiating Phase 3. During the quarter, we successfully completed GMP manufacturing and received clear regulatory feedback from both the FDA and ..

https://reports.pr-inside.com/alligator ... 118747.htm
Copyright PR-Inside.com 2025